NanoVibronix (NAOV) announced that an independent health service study of its UroShield is published in The Australian and New Zealand Continence Journal. The study highlights UroShield’s effectiveness in preventing catheter-associated urinary tract infections and recommends its adoption for appropriate patients with indwelling urinary catheters. Researchers found that patients using UroShield experienced an 86% reduction in UTI incidence; 70% reduction in catheter blockages; 82.8% less bladder irrigations performed and 52.3% less catheter changes. The clinicians reported improved overall catheter comfort and a reduction in the need for catheter-related interventions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAOV:
Questions or Comments about the article? Write to editor@tipranks.com